Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sol-Gel TechnologiesSLGL +0.52%56 Debt-to-Equity is 0.02 as of Mar. 2026, which is 33% below its 10-year median of 0.03. GuruFocus rates SLGL with a GF Score™ of 56/100 and a GF Value™ of $65.93 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 966 Biotechnology companies, Sol-Gel Technologies ranks better than 88.1% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sol-Gel Technologies's Debt-to-Equity or its related term are showing as below:
SLGL'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.53 Med: 0.03 Max: 0.06
Current: 0.02
During the past 11 years, the highest Debt-to-Equity Ratio of Sol-Gel Technologies was 0.06. The lowest was -1.53. And the median was 0.03.
SLGL's Debt-to-Equity is ranked better than 88.1% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs SLGL: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sol-Gel Technologies Debt-to-Equity Related Terms
Sol-Gel Technologies Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sol-Gel Technologies's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SLGL vs AVXL, FATE, FHTX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Sol-Gel Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sol-Gel Technologies Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sol-Gel Technologies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sol-Gel Technologies (SLGL) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sol-Gel Technologies and its competitors. This is 33% below median its historical median of 0.03. According to the industry distribution chart, Sol-Gel Technologies ranks #115 out of 966 companies in the Biotechnology industry, placing it in the top 11.9%.
Is Sol-Gel Technologies' Debt-to-Equity too high?
Sol-Gel Technologies' current Debt-to-Equity of 0.02 is 33% below median its 10-year median of 0.03. The Biotechnology industry median Debt-to-Equity is 0.16. Sol-Gel Technologies' value of 0.02 is 87.5% below this industry median. Based on the distribution chart, Sol-Gel Technologies ranks #115 out of 966 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sol-Gel Technologies has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' Debt-to-Equity compare to AVXL and FATE?
According to the Biotechnology industry distribution chart, Sol-Gel Technologies ranks #115 out of 966 companies for Debt-to-Equity. This places Sol-Gel Technologies in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Sol-Gel Technologies' value of 0.02 is 87.5% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.16, Sol-Gel Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sol-Gel Technologies's current Debt-to-Equity of 0.02 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sol-Gel Technologies and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sol-Gel Technologies's current Debt-to-Equity is 0.02, which is 33% below median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (SLGL) is currently considered Modestly Overvalued. The stock's GF Value™ is $65.93, compared to a current price of $73.91 — trading 12.1% above its estimated fair value. The current Debt-to-Equity is 0.02, which is 33% below median its 10-year median of 0.03 and 87.5% below the Biotechnology industry median of 0.16. Sol-Gel Technologies' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sol-Gel Technologies (SLGL), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sol-Gel Technologies (SLGL) Overvalued in 2026?
Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued.
The current stock price of $73.91 is trading 12.1% above its estimated GF Value™ of $65.93.
GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.
Key valuation signals for SLGL:
Debt-to-Equity: 0.02 (33% below median its 10-year median of 0.03)
GF Value™: $65.93 vs. price of $73.91 (12.1% above fair value)
Industry Position: 87.5% below the Biotechnology median (#115 of 966)
No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
56GF Score
Get the complete analysis for SLGL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLGL has been successfully added to your 
